STOK insider trading
NasdaqGS HealthcareStoke Therapeutics, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.
About Stoke Therapeutics, Inc.
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its lead product candidates include STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy; and Zorevunersen (STK-001), an investigational new medicine for the treatment of Dravet syndrome is being evaluated in phase I/II clinical trials. The company also develops programs focused on various targets, including haploinsufficiency diseases of the central nervous system and eye. It has a license and collaboration with Biogen Inc. for the development and commercialization of zorevunersen medicine for the treatment of Dravet syndrome; and Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of genetic neurodevelopmental diseases. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.
Company website: www.stoketherapeutics.com
STOK insider activity at a glance
FilingIQ has scored 401 insider transactions for STOK since Jun 19, 2019. The most recent filing in our index is dated May 1, 2026.
Across the full history, 10 open-market purchases
and 230 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on STOK insider trades is 58.9/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest STOK Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Top insiders trading STOK
13F funds holding STOK
Frequently asked
- How many insider trades does FilingIQ track for STOK?
- FilingIQ tracks 401 Form 4 insider transactions for STOK (Stoke Therapeutics, Inc.), covering filings from Jun 19, 2019 onwards. 64 of those were filed in the last 90 days.
- Are STOK insiders net buyers or net sellers?
- Across the full Form 4 history for STOK, 10 transactions (2%) were open-market purchases and 230 (57%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does STOK insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
- What sector is STOK in?
- Stoke Therapeutics, Inc. (STOK) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $2.07B.
Methodology & sources
Every STOK insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.